Antibody-drug conjugates (ADCs) represent a rapidly growing
class of therapeutics undergoing clinical development. Wolfe
Laboratories provides expert analytical characterization,
which plays an important role during discovery, process
scale-up, manufacturing, and release/stability testing of
ADCs. Selection of appropriate analytical techniques
depends on the properties of the ADC linker, the drug and the
choice of attachment site.
Because ADCs are highly heterogeneous, Wolfe Laboratories
employs multiple orthogonal methods to fully characterize
them. The below figures illustrate how Wolfe utilized UV/VIS
spectroscopy, size exclusion (SE)-UPLC, dynamic light
scattering, and mass spectrometry to characterize the
average drug-to-antibody ratio (DAR), percent free drug,
aggregation state, and DAR heterogeneity of an
immunoconjugate system.
Average DAR by UV/VIS Spectroscopy
DAR Distribution by Mass Spectroscopy
Percent Free Drug and Aggregation State by SE-UPLC
H